

Irina Chazova

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7095886/irina-chazova-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

74
papers

8,909
citations

21
h-index

94
g-index

103
ext. papers

11,637
ext. citations

7
avg, IF

5.02
L-index

#	Paper	IF	Citations
74	2018 ESC/ESH Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2018 , 39, 3021-3104	9.5	3698
73	Macitentan and morbidity and mortality in pulmonary arterial hypertension. <i>New England Journal of Medicine</i> , 2013 , 369, 809-18	59.2	878
72	Riociguat for the treatment of pulmonary arterial hypertension. <i>New England Journal of Medicine</i> , 2013 , 369, 330-40	59.2	861
71	Olmесartan for the delay or prevention of microalbuminuria in type 2 diabetes. <i>New England Journal of Medicine</i> , 2011 , 364, 907-17	59.2	591
70	Selexipag for the Treatment of Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2015 , 373, 2522-33	59.2	521
69	Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016 , 374, 2021-31	59.2	440
68	Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016 , 374, 2009-20	59.2	382
67	Pulmonary hypertension due to left heart disease. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	209
66	Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016 , 374, 2032-43	59.2	199
65	Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. <i>Lancet, The</i> , 2010 , 376, 517-23	40	184
64	Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. <i>Lancet Neurology, The</i> , 2011 , 10, 43-53	24.1	142
63	Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. <i>International Journal of Clinical Practice</i> , 2010 , 64, 1619-31	2.9	137
62	Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus. <i>JAMA Internal Medicine</i> , 2013 , 173, 1682-92	11.5	81
61	Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2016 , 18, 82-91	6.7	65
60	Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. <i>Diabetes, Obesity and Metabolism</i> , 2006 , 8, 456-65	6.7	50
59	Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE intolerant subjects with cardiovascular Disease studies. <i>Journal of Hypertension</i> , 2012 , 30, 1004-14	1.9	46
58	Venous and arterial changes in pulmonary veno-occlusive disease, mitral stenosis and fibrosing mediastinitis. <i>European Respiratory Journal</i> , 2000 , 15, 116-22	13.6	45

57	Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial. <i>Diabetologia</i> , 2012 , 55, 36-45	10.3	42
56	Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study. <i>International Journal of Hypertension</i> , 2013 , 2013, 541689	2.4	39
55	Oxidative stress in patients with primary pulmonary hypertension. <i>Bulletin of Experimental Biology and Medicine</i> , 2002 , 133, 580-2	0.8	37
54	Comparison of single-pill strategies first line in hypertension: perindopril/amlodipine versus valsartan/amlodipine. <i>Journal of Hypertension</i> , 2015 , 33, 401-11	1.9	29
53	Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants Baseline Characteristics. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 311-8	3.8	21
52	Effects on office and home blood pressure of the lercanidipine-enalapril combination in patients with Stage 2 hypertension: a European randomized, controlled clinical trial. <i>Journal of Hypertension</i> , 2014 , 32, 1700-7; discussion 1707	1.9	18
51	Metabolically healthy obese and metabolically unhealthy non-obese phenotypes in a Russian population. <i>European Journal of Epidemiology</i> , 2017 , 32, 251-254	12.1	16
50	Overweight and Obesity in the Russian Population: Prevalence in Adults and Association with Socioeconomic Parameters and Cardiovascular Risk Factors. <i>Obesity Facts</i> , 2019 , 12, 103-114	5.1	16
49	Platelet aggregation in patients with primary pulmonary hypertension. <i>Blood Coagulation and Fibrinolysis</i> , 1996 , 7, 225-7	1	15
48	Real-life safety and effectiveness of amlodipine/valsartan combination in the treatment of hypertension. <i>Advances in Therapy</i> , 2011 , 28, 134-49	4.1	14
47	Randomized evaluation of a novel, fixed-dose combination of perindopril 3.5 mg/amlodipine 2.5 mg as a first-step treatment in hypertension. <i>Journal of Hypertension</i> , 2015 , 33, 653-61; discussion 662	1.9	12
46	Effects of the lercanidipine-enalapril combination vs. the corresponding monotherapies on home blood pressure in hypertension: evidence from a large database. <i>Journal of Hypertension</i> , 2016 , 34, 139-48	1.9	8
45	Clinical practice guidelines on the diagnosis and treatment of patients with arterial hypertension and chronic obstructive pulmonary disease. <i>Systemic Hypertension</i> , 2020 , 17, 7-34	1.6	6
44	May Measurement Month 2017 in Russia: hypertension treatment and control-Europe. <i>European Heart Journal Supplements</i> , 2019 , 21, D101-D103	1.5	5
43	Pulmonary capillary haemangiomas coexistence with sinus venosus ASD: morphometric analysis and literature review. <i>European Respiratory Journal</i> , 1998 , 12, 240-4	13.6	5
42	Russian medical society on arterial hypertension (RMSAH) Consensus of Experts on the use of radiofrequency denervation of the renal arteries in patients with arterial hypertension. <i>Systemic Hypertension</i> , 2020 , 17, 7-18	1.6	5
41	Russian Medical Society for Arterial Hypertension Expert Consensus: Hypertension and COVID-19. <i>Systemic Hypertension</i> , 2020 , 17, 35-41	1.6	4
40	COMPLAINTS ON SLEEP BREATHING DISORDER AND CARDIOVASCULAR RISK FACTORS IN RUSSIAN REGIONS: DATA FROM ESSE-RF STUDY. <i>Russian Journal of Cardiology</i> , 2018 , 152-158	1.3	4

39	Radiofrequency renal denervation with mono-electrode and multi-electrode device for treatment in patient with uncontrolled hypertension: results of a 6-month follow-up. <i>Systemic Hypertension</i> , 2020 , 17, 46-50	1.6	3
38	Uncontrolled arterial hypertension: main causes, features of pathogenesis and approaches to treatment. <i>Systemic Hypertension</i> , 2021 , 18, 13-18	1.6	3
37	Features of antihypertensive therapy and real-world prescription of selective imidazoline receptor agonists in Russia vs other countries: STRAIGHT study data analysis. <i>Terapevticheskii Arkhiv</i> , 2021 , 93, 440-448	0.9	3
36	Comparative genetic analysis of different forms of low-renin arterial hypertension. <i>Molecular Biology</i> , 2008 , 42, 521-530	1.2	2
35	Pulmonary arterial hypertension: achievements and realities of modern treatment, a look into the future. <i>Terapevticheskii Arkhiv</i> , 2021 , 93, 1009-1017	0.9	2
34	Hybrid approach for treating patient with chronic thromboembolic pulmonary hypertension and extrinsic compression of left main coronary artery. <i>Russian Open Medical Journal</i> , 2019 , 8,	1.6	2
33	Clinical features and course of arterial hypertension in patients with its various forms. <i>Systemic Hypertension</i> , 2021 , 18, 140-146	1.6	2
32	Myocardial perfusion in patients with pulmonary hypertension of different etiology 2015 ,		2
31	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH DIABETES AND PREDIABETES (2021). <i>Eurasian Heart Journal</i> , 2021 , 6-61	0.7	2
30	The effect of adherence with long-term PAP therapy on the psycho-emotional state of patients with obstructive sleep apnea syndrome. <i>Systemic Hypertension</i> , 2020 , 17, 56-60	1.6	1
29	Optimization of specific therapy for pulmonary hypertension: the possibilities of riociguat. <i>Terapevticheskii Arkhiv</i> , 2021 , 93, 1117-1124	0.9	1
28	Experience with various occluder types for endovascular hemodynamic isolation of the left atrium appendage in patients with non-valvular atrial fibrillation. <i>Journal of Arrhythmology</i> , 2021 , 28, 45-54	0.3	1
27	Management of patients with arterial hypertension and atrial fibrillation. <i>Systemic Hypertension</i> , 2021 , 18, 105-128	1.6	1
26	Efficacy and safety of azilsartan medoxomil in various doses in patients with metabolic disorders. <i>Systemic Hypertension</i> , 2021 , 18, 130-139	1.6	1
25	Long-term positive airway pressure therapy in patients with various forms of atrial fibrillation and obstructive sleep apnea. <i>Kardiologicheskii Vestnik</i> , 2020 , 72-78	0.2	1
24	Expert consensus. Effect of antihypertensive therapy on cognitive functions. <i>Systemic Hypertension</i> , 2021 , 18, 5-12	1.6	1
23	Changes in the receptor activity of α -adrenoreceptors of human T-lymphocytes under the effect of α -agonists. <i>Molecular Biology</i> , 2016 , 50, 880-886	1.2	1
22	Impact of metabolic syndrome parameters and different fat depots on arterial stiffness in patients with abdominal obesity. <i>Systemic Hypertension</i> , 2020 , 17, 55-62	1.6	1

21	Assessment of epicardial adipose tissue by echocardiography for risk stratification in young adults with abdominal obesity. <i>Systemic Hypertension</i> , 2020 , 17, 74-79	1.6	1
20	The incidence of cardiovascular and cerebrovascular complications in patients with uncontrolled hypertension. <i>Terapevticheskii Arkhiv</i> , 2022 , 94, 94-99	0.9	1
19	Multiple rare and common variants in APOB gene locus associated with oxidatively modified low-density lipoprotein levels. <i>PLoS ONE</i> , 2019 , 14, e0217620	3.7	0
18	First results of Russian multicenter prospective clinical study VICTORY II: Vamloset [®] and Co-Vamloset effectiveness and safety in patients with stage 2 and 3 arterial hypertension. <i>Systemic Hypertension</i> , 2020 , 17, 36-47	1.6	0
17	Characteristics of patients with chronic thromboembolic pulmonary hypertension according to the Russian National Registry. <i>Terapevticheskii Arkhiv</i> , 2021 , 93, 1058-1065	0.9	0
16	Influence of demographic characteristics on the clinical course and results of therapy in patients with precapillary pulmonary hypertension. <i>Terapevticheskii Arkhiv</i> , 2021 , 93, 283-289	0.9	0
15	Gender-age peculiarities of smoking and diabetes mellitus role in the development of myocardial infarction in patients with arterial hypertension. <i>Systemic Hypertension</i> , 2020 , 17, 24-31	1.6	0
14	Role of cardiac computed tomography in endovascular isolation of the left atrial appendage. <i>Kardiologiya I Serdechno-Sosudistaya Khirurgiya</i> , 2022 , 15, 46	0.3	
13	Speckle-tracking echocardiography in 3D mode in assessing the deformation of the myocardium and identifying subclinical cardiotoxicity during chemotherapy in breast cancer patients with arterial hypertension. <i>Systemic Hypertension</i> , 2020 , 17, 42-47	1.6	
12	Implementation of the organoprotective properties of fixed combinations of valsartan, amlodipine and hydrochlorothiazide (Vamloset [®] and Co-Vamloset) in patients with grade 2 and 3 hypertension in the Russian clinical study VICTORY II. <i>Systemic Hypertension</i> , 2020 , 17, 59-70	1.6	
11	The clinical case of successful combined treatment of refractory arterial hypertension. Case report. <i>Terapevticheskii Arkhiv</i> , 2021 , 93, 1086-1090	0.9	
10	Arterial hypertension in elderly and senile patients: clinical characteristics and treatment quality (according to the national register of arterial hypertension). <i>Siberian Medical Journal</i> , 2019 , 34, 73-86	0.3	
9	Pulmonary hypertension in a patient with kyphoscoliotic heart disease. <i>Siberian Medical Journal</i> , 2019 , 34, 172-178	0.3	
8	STRUCTURAL CHANGES OF THE PULMONARY ARTERIES AFTER BALLOON PULMONARY ANGIOPLASTY IN PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION. <i>Eurasian Heart Journal</i> , 2020 , 12-20	0.7	
7	From palpation of the pulse to cuff-free methods: evolution of arterial pressure measurement methods. <i>Terapevticheskii Arkhiv</i> , 2021 , 93, 526-531	0.9	
6	PAP-therapy adherence in patients with obstructive sleep apnea and cardiovascular diseases. <i>Systemic Hypertension</i> , 2020 , 17, 37-43	1.6	
5	Efficacy and safety of using a fixed-dose combination of azilsartan medoxomil and chlorthalidone in patients with diabetes mellitus. <i>Systemic Hypertension</i> , 2020 , 17, 68-73	1.6	
4	Consensus of experts from the Russian Medical Society of Arterial Hypertension. Arterial hypertension and erectile dysfunction. <i>Systemic Hypertension</i> , 2021 , 18, 69-79	1.6	

- | | | |
|---|---|-----|
| 3 | Treatment of patients with arterial hypertension in clinical practice in 2010-2020 (according to the national register of hypertension). <i>Terapevticheskii Arkhiv</i> , 2022 , 94, 9-17 | 0.9 |
| 2 | The assessment of renal function during the therapy of arterial hypertension with azilsartan medoxomil in patients with obesity or overweight and concomitant metabolic disorders. <i>Terapevticheskii Arkhiv</i> , 2021 , 93, 1510-1515 | 0.9 |
| 1 | The impact of left atrial appendage occlusion on the rhythm control in atrial fibrillation: a prospective cohort study. <i>Kardiologicheskii Vestnik</i> , 2022 , 17, 73 | 0.2 |